I do not find this legislative solution to a market problem viable. Usually, markets adjust fast and make the legislation moot, or someone else ends up paying (subsidizing) for others, which is the problem we are having right now.
The good news is that rebates to insurers by pharmacy benefit manager will probably be banned by this administration, and that is a more practical solution to the problem.
An expert told me that the excessive cost of insulin helps lower insurance cost for healthy people, or increase profit margins by health insurance companies by about ~1%.
And there is data that indicates that some people with type II diabetes cut down on insulin because of this.
Also, open insulin would be more viable since the pharmacy benefit managers would likely not sell, or give rebates, on a less expensive version of insulin.
I think banning rebates is a step forward, but, again, do not underestimate powerful lobbying groups that can make this change in regulation a moot point.